Guardant Health GH
United StatesHealthcare · Diagnostics & ResearchUSD
199.84 USD (+18.7%)
25 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Guardant Health is a precision genomic diagnostics company that develops and commercializes liquid biopsy tests for cancer detection and monitoring, selling its products to oncologists, hospitals, and pharmaceutical companies.
Key points
from its scores- ✓Good share-price trend9.8
- ✓Strong growth9.7
- ✓High-quality business8.7
- ✕Little or no dividend0.5
- ✕Demanding valuation1.0
AI analysis
bottom line, main risk, context and newsHold for its high growth and balance sheet strength, but assume that profitability and valuation are the weak points to watch.
Guardant Health shows very strong revenue growth (44.30%) and a healthy balance sheet with net cash (Net Debt/EBITDA of -1.49), although it remains unprofitable at the operating level (operating margin of -38.25%) and its valuation is demanding (FCF yield of 0.12).
The main risk is the lack of operating profitability (margin of -38.25%) in a demanding valuation environment, which depends on revenue growth translating into positive margins before the market demands results.
Context and risks
No recent relevant news and no material exposure to current macro factors (rates, oil, shipping routes). The genomic diagnostics business does not depend on commodities or affected supply routes, and its net cash balance sheet insulates it from the rise in long-term rates.
Is Guardant Health stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 459% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / sales | 19.1 | 3.4 | +459% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.0 out of 10 (median for Healthcare: 4.7).
Average analyst target: 199.84 USD, +18.7% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 8.7 (sector 5.5), Growth 9.7 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −402.8
- EV / EBITDA
- −54.0
- Price / book
- −100.9
- Price / sales
- 19.1
- Market cap
- 22.6B USD
- Enterprise value
- 23.2B USD
Profitability
- ROA
- −18.1%
- Gross margin
- 65.0%
- Operating margin
- −38.2%
- Net margin
- −38.3%
- Free cash flow
- 26.6M USD
- FCF yield
- 0.1%
Solvency
- Total debt
- 1.7B USD
- Net debt
- 643.5M USD
- Cash
- 1.1B USD
- EBITDA
- −430.6M USD
- Net debt / EBITDA
- −1.49
- Current ratio
- 4.03
- Quick ratio
- 3.53
Growth
- Revenue growth
- +44.3%
- EPS (TTM)
- −3.50 USD
- EPS (forward)
- −0.42 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 1.58
- Analyst consensus
- Strong buy (25)
- Target price
- 199.84 USD
- 52-week range
- 61.00 – 191.05
Recent news
All GH news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Guardant Health
Is Guardant Health stock cheap or expensive?
On Price / sales, it trades 459% above the Healthcare median. Valuation score: 1.0 out of 10 (median for Healthcare: 4.7). Average analyst target: 199.84 USD, +18.7% versus the price. This is not investment advice.
What score does Guardant Health get on MeridIAn Screener?
It scores 5.7 out of 10, rank 1,245 of 2,130 (better than 39% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Guardant Health worth on the stock market?
Its market capitalisation is 22.6B USD and its enterprise value, debt included, is 23.2B USD.
How much debt does Guardant Health have?
Its net debt (debt minus cash) is 643.5M USD.
Does Guardant Health pay a dividend?
It pays no dividend, or almost none.
How has Guardant Health stock performed over the last year?
It has risen 162.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 61.00 and 191.05 USD. Past performance does not guarantee future results.
What do analysts think of Guardant Health?
25 analysts cover it; their average recommendation is “Strong buy” and their average target is 199.84 USD (+18.7% versus the price). It is an estimate, not market data.